(Q28444994)

English

MET Amplification

genetic variant

AMPLIFICATION

In more languages

Statements

Transcript Amplification

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/270

human chromosome 7

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/270

116312459

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/270

116436396

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/270

biological variant of

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/270

positive therapeutic predictor for

determination method

CIViC evidence level C

CIViC 3-star trust rating

medical condition treated

non-small-cell lung carcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/735

Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification

determination method

CIViC evidence level C

CIViC 2-star trust rating

medical condition treated

adenocarcinoma of the lung

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/836

Response to Crizotinib Observed in Lung Adenocarcinoma with MET Copy Number Gain but without a High-Level MET/CEP7 Ratio, MET Overexpression, or Exon 14 Splicing Mutations

determination method

CIViC evidence level C

CIViC 2-star trust rating

medical condition treated

squamous cell carcinoma of the lung

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/890

Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement

determination method

CIViC evidence level C

CIViC 3-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1565

Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor

determination method

CIViC evidence level D

CIViC 4-star trust rating

medical condition treated

non-small-cell lung carcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1566

MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations

Crizotinib / Vemurafenib combination therapy

determination method

CIViC evidence level C

CIViC 4-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1588

MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.

determination method

CIViC evidence level C

CIViC 3-star trust rating

medical condition treated

adenocarcinoma of the lung

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1692

Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling

determination method

CIViC evidence level C

CIViC 2-star trust rating

medical condition treated

non-small-cell lung carcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1713

Responses to Crizotinib Can Occur in High-Level MET-Amplified Non-Small Cell Lung Cancer Independent of MET Exon 14 Alterations

determination method

CIViC evidence level C

CIViC 3-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1714

Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary

crizotinib / Cetuximab combination therapy

determination method

CIViC evidence level D

CIViC 3-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1979

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer

determination method

CIViC evidence level C

CIViC 3-star trust rating

medical condition treated

gastric adenocarcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/689

Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence

negative therapeutic predictor for

determination method

CIViC evidence level D

CIViC 4-star trust rating

medical condition treated

non-small-cell lung carcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/733

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

determination method

CIViC evidence level C

CIViC 2-star trust rating

medical condition treated

adenocarcinoma of the lung

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1392

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers

determination method

CIViC evidence level C

CIViC 2-star trust rating

medical condition treated

adenocarcinoma of the lung

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1392

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers

Identifiers

CIViC variant ID

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/270

HGVS nomenclature

no value

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/270

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28444994&oldid=2014801371"